Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Pharmacogenomic characterization of US FDA-approved cytotoxic drugs.

Peters EJ, Motsinger-Reif A, Havener TM, Everitt L, Hardison NE, Watson VG, Wagner M, Richards KL, Province MA, McLeod HL.

Pharmacogenomics. 2011 Oct;12(10):1407-15. doi: 10.2217/pgs.11.92.

2.

Use of cell lines in the investigation of pharmacogenetic loci.

Zhang W, Dolan ME.

Curr Pharm Des. 2009;15(32):3782-95. Review.

3.

Genome-wide discovery of loci influencing chemotherapy cytotoxicity.

Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL.

Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11809-14. Epub 2004 Jul 28.

4.

Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.

Kim T, Han N, Sohn M, Oh JM, Lee EK, Ji E, Kim IW.

Basic Clin Pharmacol Toxicol. 2015 May;116(5):438-44. doi: 10.1111/bcpt.12341. Epub 2014 Nov 21.

5.

Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.

Frueh FW, Amur S, Mummaneni P, Epstein RS, Aubert RE, DeLuca TM, Verbrugge RR, Burckart GJ, Lesko LJ.

Pharmacotherapy. 2008 Aug;28(8):992-8. doi: 10.1592/phco.28.8.992.

PMID:
18657016
6.

Copy number polymorphisms and anticancer pharmacogenomics.

Gamazon ER, Huang RS, Dolan ME, Cox NJ.

Genome Biol. 2011;12(5):R46. doi: 10.1186/gb-2011-12-5-r46. Epub 2011 May 25.

7.

Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.

Vivot A, Boutron I, Ravaud P, Porcher R.

Genet Med. 2015 Sep;17(9):733-8. doi: 10.1038/gim.2014.181. Epub 2014 Dec 18.

PMID:
25521333
8.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
9.

Marking off new territory in the search for anticancer compounds: epigenetic mechanisms add complexity and promise to cancer research efforts.

Nelson B.

Cancer Cytopathol. 2012 Jun 25;120(3):143-4. doi: 10.1002/cncy.21212. No abstract available.

10.

Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci.

Gamazon ER, Huang RS, Cox NJ, Dolan ME.

Proc Natl Acad Sci U S A. 2010 May 18;107(20):9287-92. doi: 10.1073/pnas.1001827107. Epub 2010 May 4.

11.

Identification and replication of loci involved in camptothecin-induced cytotoxicity using CEPH pedigrees.

Watson VG, Motsinger-Reif A, Hardison NE, Peters EJ, Havener TM, Everitt L, Auman JT, Comins DL, McLeod HL.

PLoS One. 2011 May 5;6(5):e17561. doi: 10.1371/journal.pone.0017561.

12.

Activity-based proteome profiling of potential cellular targets of Orlistat--an FDA-approved drug with anti-tumor activities.

Yang PY, Liu K, Ngai MH, Lear MJ, Wenk MR, Yao SQ.

J Am Chem Soc. 2010 Jan 20;132(2):656-66. doi: 10.1021/ja907716f.

PMID:
20028024
13.

Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.

Konecny G, Untch M, Slamon D, Beryt M, Kahlert S, Felber M, Langer E, Lude S, Hepp H, Pegram M.

Breast Cancer Res Treat. 2001 Jun;67(3):223-33.

PMID:
11561768
14.

Publication of clinical trials supporting successful new drug applications: a literature analysis.

Lee K, Bacchetti P, Sim I.

PLoS Med. 2008 Sep 23;5(9):e191. doi: 10.1371/journal.pmed.0050191.

15.

Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.

Shea MB, Roberts SA, Walrath JC, Allen JD, Sigal EV.

Clin Cancer Res. 2013 Jul 15;19(14):3722-31. doi: 10.1158/1078-0432.CCR-13-0316. Epub 2013 May 10.

16.

U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.

Chen DT, Wynia MK, Moloney RM, Alexander GC.

Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1094-100. doi: 10.1002/pds.1825.

PMID:
19697444
17.
18.

Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms.

Uziel O, Beery E, Dronichev V, Samocha K, Gryaznov S, Weiss L, Slavin S, Kushnir M, Nordenberg Y, Rabinowitz C, Rinkevich B, Zehavi T, Lahav M.

PLoS One. 2010 Feb 9;5(2):e9132. doi: 10.1371/journal.pone.0009132.

19.

Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses.

Hart B, Lundh A, Bero L.

BMJ. 2012 Jan 3;344:d7202. doi: 10.1136/bmj.d7202.

PMID:
22214754
20.

Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity.

Dolan ME, Newbold KG, Nagasubramanian R, Wu X, Ratain MJ, Cook EH Jr, Badner JA.

Cancer Res. 2004 Jun 15;64(12):4353-6.

Supplemental Content

Support Center